Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockman6767on Jun 04, 2021 8:46am
47 Views
Post# 33328427

RE:Gobb, we'll know soon but if they went through the

RE:Gobb, we'll know soon but if they went through the "making a 100M$ deal with kedrion"  --  What you realy mean, is they gave away the store to Kedrion for $5 M (if the FDA is positive) on Ryplazim, and they gave away to Kedrion some $30 M if the voucher is granted by the FDA. There is nothing positive about these "deals."

We need to look for future  back door payments to Thomson interests  to hide the revenie from the  $1 B lawsuit or none of this "deal" makes any sense.
<< Previous
Bullboard Posts
Next >>